Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells aim to keep HIV in check without daily pills

NCT ID NCT06252402

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether specially engineered immune cells (CMV-HIV CAR T cells) can help control HIV in people already on antiretroviral therapy (ART). The goal is to see if these cells can persist in the body and keep the virus suppressed, potentially allowing long-term remission. The study involves 15 adults with well-controlled HIV and no other major health issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact

  • UCSD, Division of Infectious Diseases and Global Public Health

    RECRUITING

    San Diego, California, 92093, United States

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.